Prometic Announces Realignment of its Clinical Program Priorities for 2018

February 20, 2018

Responsive image

IPF and Alström Syndrome; Top priorities for PBI-4050 clinical development
Unique anti-fibrotic mechanism of action supporting rationale for the development of first-in-class drug candidates
Plasminogen to target acute acquired deficiencies and wound healing


Category: Precious Metals